Mohamad E. Allaf, M.D.
Director, Minimally Invasive and Robotic Surgery
Dr. Allaf is Professor of Urology, Oncology, and Biomedical Engineering at the Brady Urological Institute and Director of Minimally Invasive and Robotic Urological Surgery at the Johns Hopkins Hospital. He joined the staff after receiving his undergraduate and medical degrees from the Johns Hopkins University and completing his residency and advanced training in Urology at Johns Hopkins, as well.
As a urologic oncologist, his main clinical focus includes the treatment of kidney tumors and prostate cancer. While expert in both open and minimally invasive surgery, he specializes in ROBOTIC approaches to these diseases and is amongst the busiest robotic surgeons in the world. The following is a list of robotic procedures he performs on a regular basis:
Dr. Allaf also runs a research laboratory aimed at decreasing the morbidity associated with the treatment of urologic cancers. He oversees a large registry of patients who have small kidney tumors and elect for careful and active observation. Additionally, given his background as a biomedical engineer, he is a leader in developing future technological advancements in the field of robotic and minimally invasive surgery. An example of this is the use of real-time elastography imaging during robotic prostatectomy to regain tactile feedback during this delicate procedure.
Dr. Allaf has been the recipient of numerous academic awards and has been invited nationally and internationally to demonstrate robotic surgery and lecture on robotic prostatectomy and kidney surgery. He has written and published numerous research articles, textbook chapters, patents and video presentations in the field of Laparoscopic and Robotic Urologic Surgery.
Dr. Allaf routinely performs surgery on international patients and has personally performed surgery abroad. His goal is to provide you with the best medical care possible while coordinating the care plan with your local physicians. Dr. Allaf prefers setting up an appointment by phone after receiving the relevant medical records.
Based on this phone appointment a care plan will be formulated allowing you to plan your trip to Baltimore efficiently. For inquiries please call Dr. Allaf's office at +1 410-502-7710 or email him directly at firstname.lastname@example.org.
Trinity J. Bivalacqua, M.D., Ph.D., is the R. Christian B. Evensen Professor of Urology and Oncology and Director of Urologic Oncology at the James Buchanan Brady Urologic Institute . He was born in New Orleans, Louisiana and graduated from Tulane University with undergraduate, graduate and medical degrees. He joined the faculty after completing his General Surgery and Urology training at Johns Hopkins Hospital. He also completed an American Urological Association (AUA) Foundation Post-Doctoral Fellowship from the AUA Care Foundation.
Dr. Bivalacqua has an active clinical practice in Urologic Oncology and Sexual Dysfunction. As a member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dr Bivalacqua participates in multidisciplinary approaches to the treatment of a variety of genitourinary cancers. He has a special interest in cancers of the prostate and bladder with an emphasis on organ sparing therapies, minimally invasive techniques (nerve-sparing robotic assisted laparoscopic radical prostatectomy and robotic-assisted laparoscopic radical cystectomy) and orthotopic bladder substitution (neobladder). Although he has a busy surgical practice, he maintains an active research portfolio in order to improve outcomes of cancer patients. A major focus of his research lab is development of pre-clinical models of urothelial carcinoma to test systemic and intravesical immunotherapies and nano-particular based chemotherapies. Also, he heads the tissue-engineering lab which focuses on regenerative approaches to enhance autonomic nerve function and development of tissue-engineered urinary tissue with the ultimate goal of production of a neo-urinary conduit and bladder.
Dr. Bivalacqua's basic, translational and clinical research is funded by peer-reviewed awards and he has recently been acknowledged for his accomplishments in research with several grants including a Career Development Award from the National Institute of Health (NIH), Greenberg Bladder Cancer Institute, and the AUA "Rising Star" Award. He also serves on the Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN) and a member of the AUA Leadership Program.
Dr. Misop Han is professor of urology and oncology at the Johns Hopkins Hospital. Dr. Han is a board-certified urologist whose main clinical focus is in urological oncology with a special emphasis on prostate and kidney cancers. When meeting with a patient, Dr. Han carefully reviews the patient's individual situation to determine with the patient the best approach to treatment.
Dr. Han specializes in:
- Prostate Cancer
- Robotic Prostatectomy
- Robotic Nephrectomy
- Nerve-sparing Prostatectomy
- Laparoscopic Nephrectomy
- Benign Prostatic Hyperplasia (BPH)
- Kidney Cancer
At Johns Hopkins Hospital, Dr. Han is actively involved in researching what happens to men following surgery for prostate cancer. He has published extensively in these subjects. Click here for his publications. Click here for the outcome of radical prostatectomy and prediction modeling (Han Tables). Dr. Han's research and clinical trials also involve urologic robotics for image-guided surgery.
Dr. Han has received international and national recognition for his research involving the outcomes of surgeries for patients with prostate cancer. He is a member of the American Urological Association and the American Medical Association, and is certified by the American Board of Urologists.
Dr. Johnson is an Assistant Professor of Urology and Oncology. He was recruited to the faculty after completing his urologic oncology fellowship at Johns Hopkins. Prior to Hopkins, Dr. Johnson received his undergraduate degree from Dartmouth College, his medical degree from the University of Washington, and completed his residency at Washington University in St. Louis.
As a fellowship-trained urologic oncologist, Dr. Johnson has received advanced training in treating prostate, kidney, and bladder cancers. He treats these diseases with both open and minimally-invasive/robotic approaches. This includes radical prostatectomy, radical/partial nephrectomy, and radical cystectomy.
Utilizing the latest technologies and surgical techniques, Dr. Johnson creates treatment plans that emphasize a lasting cure and speedy recovery. He believes that the keys to exceptional patient care are a prompt evaluation and excellent communication. His goal is to provide the best possible care, working with referring physicians to ensure patients transition back home in a seamless manner.
Dr. Johnson’s research laboratory focuses on using genomic and computational tools for personalized, preventive, and predictive cancer care. Having received training in computational biology and Systems Biology, he is funded by the National Institutes of Health to advance “Big Data” efforts for precision medicine in kidney cancer using personalized tumor sequencing. He holds additional grant funding in bladder cancer immunotherapy and prostate cancer research.
Dr. Johnson has received numerous awards, for his teaching and research efforts. He has authored many scientific publications, including research articles, videos of surgical techniques, and textbook chapters.
Dr. Johnson welcomes patient inquiries and referrals. Contacting him directly by phone (410-614-9156) or email (email@example.com) will allow him to collect the necessary records, prior to a clinic appointment.
Project Title: Integrated computational and biological identification of personalized tumor-specific neoantigens in renal cell carcinoma
Source: Urology Care Foundation Research Scholar
Description: This study utilizes whole-exome sequencing of renal cell carcinoma tumors to identify tumor-specific antigens
Project Title: Molecular analysis and precision medicine in renal cell carcinoma
Source: NIH Mentored Career Development Award in Biomedical Big Data Science (K01)
Description: This study focuses on the analysis of genome-scale molecular data to discover predictors of medical treatment success in patients with renal cell carcinoma.
Project Title: Rapid lymphocyte enrichment and expansion using tumor-specific neoantigens in urothelial cell carcinoma
Source: Greenberg Bladder Cancer Institute
Description: This study utilizes a novel technology to select lymphocyte clones that are stimulated by computationally-predicted, tumor-specific peptides.
Project Title: Longitudinal blood-based analyses in post-prostatectomy men
Source: Patrick C. Walsh Prostate Cancer Research Fund
Description: This study utilizes collects longitudinal blood samples in post-prostatectomy men and performs proteomic analyses to determine a blood-based signature of the prostate and prostate cancer.
Appointments: 410 955-6100
Dr. Brian Matlaga is the Stephens Professor of Urology at the Johns Hopkins University School of Medicine and also serves as the Director of Ambulatory Care for the James Buchanan Brady Urological Institute. Dr. Matlaga received his undergraduate degree from Dartmouth College, and his Medical Degree and a Master of Public Health degree from Tulane University. He then completed his internship in surgery and residency in urology at Wake Forest University; his subsequent fellowship at Indiana University was supported by an American Foundation for Urologic Disease Research Scholarship.
Dr. Matlaga is an internationally recognized expert in the medical and surgical management of patients with urinary stone disease, and he is the Director of Stone Disease for the Brady Urological Institute. This expertise is built on his academic investigations of the pathophysiology and epidemiology of stone formation, as well as into the advancement of minimally invasive surgical techniques. A frequent contributor to the medical press, Dr. Matlaga’s research has received both national and international awards; in 2014, he was the recipient of the Endourological Society’s Arthur D. Smith Endourology Lectureship, which was given in recognition of accomplishments in the first ten years of his career.
Dr. Matlaga is an independently funded investigator, and presently is the Principal Investigator for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Urologic Diseases in America project. Dr. Matlaga sits on numerous editorial boards as well as advisory committees and guidelines panels for the American Urological Association, the American Board of Urology, the Endourological Society, and the National Institutes of Health. He recently served as Vice Chair of the American Urological Association’s Surgical Management of Stones Guidelines, and in 2016-2017 will be serving as Task Force Chair for the Examination Committee of the American Board of Urology. He also serves on the Board of Directors for the Society of Academic Urologists as well as the Endourological Society, and he was recently named the Associate Director of Education for the Endourological Society. Dr. Matlaga coordinates the enterprise-wide research program at Johns Hopkins Aramco Healthcare, a joint venture between Johns Hopkins Medicine and Saudi Aramco that is based in the Kingdom of Saudi Arabia.
Alan W. Partin, M.D., Ph.D., is the author or co-author of more than 550 scientific articles, serves on numerous editorial boards and is editor-in-chief of Urology Case Reports and editor of the Campbell-Walsh urology text. He has been honored with many awards, including the Hopkins Young Investigators Award, the Pfizer Scholars in Urology Award in 1996, and the "Gold- Cystoscope" award in 2001. In 2004, Dr. Partin was named director of the Department of Urology at the Brady Urological Institute and urologist-in-chief of The Johns Hopkins Hospital.
Dr. Partin is an expert in assessing prognosis and making predictions for men with prostate cancer. The creation of The Partin Tables, which can predict with 95 percent accuracy a man's likelihood of being cured by treatment, made his research famous. Dr. Partin's laboratories and clinical and surgical interests focus on developing and testing new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians. His laboratories have investigated many new "PSA-like" serum tests, many of which have subsequently become available for clinical utilization. He also has an academic and clinical interest in the basic science investigation of new, novel proteins which may help in detection and staging of prostate cancer.
Dr. Partin received his undergraduate degree in chemistry from the University of Mississippi where he was an Academic All-American football player. He received his medical degree and his Ph.D. in pharmacology and molecular sciences from Johns Hopkins University where he continued his post-doctoral training.
410-955-6100 Johns Hopkins Hospital Outpatient Center
443-997-1849 Johns Hopkins Bayview Medical Center
Dr. Pavlovich came to Johns Hopkins after completing a Urologic Oncology fellowship at the National Cancer Institute. His practice is dedicated primarily to the treatment of prostate, kidney and bladder cancer, as well as to the treatment of benign prostatic diseases. He is experienced in open, laparoscopic, and robotic minimally invasive surgery for the management of urologic tumors, including nerve-sparing laparoscopic and robot- assisted radical prostatectomy, laparoscopic and robotic nephrectomy and partial nephrectomy, and robotic radical cystectomy.
A particular expertise of his is the robotic extraperitoneal (or retroperitoneal) approach to the prostate and kidney for patients with prostate or kidney cancer. This approach, which avoids entry into the abdominal cavity, is ideally suited for patients that have had prior abdominal or inguinal operations (e.g. hernia repairs, appendectomy, colectomy) or who have inflammatory conditions (e.g. Crohn’s disease, ulcerative colitis, diverticulitis) that might make an abdominal robotic approach more hazardous.
Dr. Pavlovich’s research has been funded by the National Institutes of Health, Department of Defense, industry, and through institutional grants. He continues to work on early detection and risk stratification of prostate and kidney cancer using novel noninvasive urinary, blood, and imaging tests. As Director of Urologic Oncology at Johns Hopkins Bayview Medical Center, he continues to treat cancer with an emphasis on minimizing morbidity and maximizing quality of life, while exposing his patients to the latest treatment options and techniques. In addition, as Fellowship Director of Urologic Oncology for the Brady Urological Institute, he oversees the selection and training of the next generation of leaders in the field.
Dr. Pavlovich is accepting new patients and is delighted to offer second opinions regarding the treatment of any urologic malignancy.
Appointments: 410 955 6100
Office: 410 502 5984
Dr. Phillip Pierorazio is an Assistant Professor of Urology and Oncology in the Brady Urological Institute at Johns Hopkins University. Dr. Pierorazio is originally from New York, received his undergraduate degree from Georgetown University in Washington, DC and his medical degree from Columbia University, College of Physicians & Surgeons in New York City where he completed a Doris Duke Clinical Research Fellowship in Urologic Oncology.
Dr. Pierorazio has expertise in all malignancies of the urinary tract and performs both open and minimally-invasive surgeries including laparoscopic and robotic surgeries of the kidney, bladder, prostate and retroperitoneal lymph node dissection for testicular cancer. He has a special interest in kidney cancer, including partial nephrectomy for early stage disease and high-risk surgeries for patients with advanced cancers.
His research interests parallel his clinical practice, including high-risk prostate and urothelial cancer. He has a special interest in testicular and kidney cancer (renal cell carcinoma), studying both advanced and early-stage disease. He runs the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry - one of the largest active surveillance registries for patients with small kidney tumors. He sits on both the AUA and National Comprehensive Cancer Network (NCCN) Guidelines Committees for Kidney Cancer.
He is also the Director of the Division of Testicular Cancer, a member of the NCCN Guidelines committee, and works with a number of testicular cancer advocacy groups around the country. He runs the testicular cancer "Go-Team" and coordinates the departments research efforts in testicular cancer.
Dr. Pierorazio is the recipient of a number of academic awards including the American Urologic Association Essay Contest, NCCN Young Investigator Award, and has presented his research at a number of national and international meetings. He has written and published numerous research articles, textbook chapters, and video presentations in the field Urologic Oncology.
Dr. Smith is an Assistant Professor of Urology at Johns Hopkins University and the Director of Johns Hopkins Urologic Oncology at Sibley Hospital. She completed her urologic residency at Cleveland Clinic, and urologic oncology fellowship at National Cancer Institute.
Dr. Smith is highly trained in advanced urologic surgery, including both open and minimally invasive approach to oncologic diseases and the use of latest robotic technologies. Her clinical expertise spans a wide area of urologic malignancies with particular interest in bladder and kidney cancers. In bladder cancer surgery she specializes in complex urinary diversions, including continent orthotopic neobladder and continent catheterizable pouch techniques. In kidney cancer her particular area of expertise is partial nephrectomy, with the goal of oncologically-sound maximum nephron-sparing surgery.
Dr. Smith has lectured internationally and authored chapters on urothelial and kidney cancer. Her current research focuses on elucidating risk factors for development of bladder cancer and overcoming resistance to conventional therapy regimens, including development of personalized targeted therapies.
Dr. Wright is Director of Neurourology and Chief of Urology at Johns Hopkins Bayview Medical Center. He completed a fellowship in female urology, reconstructive urology and urodynamics. His clinical and research interests are in male and female urinary incontinence, complex voiding dysfunction and pelvic genitourinary reconstructive surgery.
- Lower Urinary Tract Reconstruction
- Pelvic Floor Disorders
- Pelvic Organ Prolapse
- Urethral Stricture
Nerve-Sparing Robotic Radical Prostatectomy a minimally invasive surgical technique to remove the prostate gland in patients diagnosed with prostate cancer using robotic assisted surgery.
Laparoscopic Radical Nephrectomy: a minimally invasive surgical technique to remove a diseased kidney (e.g. from cancer, blockage, or stone disease).
Laparoscopic Partial Nephrectomy: a minimally invasive surgical technique to remove a small renal tumor, while preserving the remainder of the kidney.
Percutaneous Ablation Of Renal Tumorsa minimally invasive surgical technique of renal tumor ablation using a needle placed through the skin
|Extracorporeal shock wave lithotripsy (ESWL) a non invasive technique that uses sound waves (also called shock waves) to break a kidney stone into small pieces
Ureteroscopy: is a procedure using a thin telescope (ureteroscope), which is passed through the urethra (channel through which urine flows out of the bladder) used to treat stones within kidney or ureter.
Percutaneous Nephrolithotomy (PCNL): a minimally invasive technique for removing large kidney stones through a small incision made in the skin.
Laparoscopic Live Donor Nephrectomy:is a minimally invasive technique of kidney donation, which provides the least amount of discomfort for the donor while maintaining the health and quality of the kidney for transplantation.
|Laparoscopic Pyeloplasty:a minimally invasive surgical technique used to reconstruct the drainage system of the kidney in patients suffering from blockage of a kidney at the ureteropelvic junction (i.e. the connection between the ureter or drainage tube and the kidney).
Laparoscopic Renal Cyst Ablationa minimally invasive surgical technique to excise symptomatic kidney cyst.
|Laparoscopic Retroperitoneal Lymph Node Dissection (RPLND)a minimally invasive surgical technique to remove retroperitoneal lymph nodes in patients with testicular cancer.
|Laparoscopic Pelvic Organ Prolapse Repair (COLPOSUSPENSIONa minimally invasive surgical technique for resuspension of the vagina, bladder, and rectum in women with prolapse.
|Laparoscopic Adrenalectomya minimally invasive surgical technique for removing a diseased or cancerous adrenal gland.
Warning: these video clips include footage from an actual surgery which some viewers may find difficult to watch.Laparoscopic Live Donor Nephrectomy Laparoscopic Pelvic Organ Prolapse Repair(COLPOSUSPENSION)